氨曲南治疗肿瘤患者下呼吸道感染的成本-效果分析

Cost-effectiveness analysis of aztreonam in the treatment of cancer patients with lower respiratory tract infection

目的:评价氨曲南治疗肿瘤患者下呼吸道感染的成本-效果,促进合理用药,降低医疗费用。方法:利用已有文献资料,运用药物经济学成本-效果分析方法,对氨曲南与头孢他啶治疗肿瘤患者下呼吸道感染进行药物经济学评价。结果与结论:两组方案治疗肿瘤患者下呼吸道感染的临床有效率、治愈率无显著性差异,但氨曲南组的细菌清除率优于头孢他啶组,头孢他啶的经济学成本优于氨曲南。

Objective： To evaluate the cost-effectiveness of aztreonam in the treatment of cancer patients with lower respiratory tract infection, promote rational use of the drugs and decrease the treatment cost. Methods： The cost-effectiveness was analyzed with medical cost-effectiveness analyzing method aztreonam and cefiazidime were compared in the treatment of cancer patients with lower respiratory tract infection based on the published reference data. Results and Conclusion： There is no obvious difference between these two drugs in clinical effective rate and cure rate of cancer patients with lower respiratory tract infection, but the bacteria clearance ratio of aztreonam was superior to that of cefiazidime. Cost-effectiveness ratio of ceftazidime is superior to that of aztreonam.